Profunda Medical Corp. (Prof): Modelo de Negócios Canvas [Jan-2025 Atualizado]

A profunda Medical Corp. (Prof) surge como inovadora inovadora no cenário de tecnologia médica, se posicionando estrategicamente na interseção de soluções de diagnóstico avançado e tecnologias terapêuticas não invasivas. Ao elaborar meticulosamente um modelo de negócios abrangente que aproveita a engenharia médica de ponta, as plataformas de tecnologia proprietária e as parcerias estratégicas, a empresa está revolucionando as abordagens de tratamento urológico com inovações centradas no paciente e orientadas por precisão que prometem transformar os resultados clínicos e redefinir estratégias médicas .

Profunda Medical Corp. (Prof) - Modelo de Negócios: Principais Parcerias

Instituições de pesquisa de dispositivos médicos

Instituição de pesquisa	Foco de colaboração	Ano estabelecido
Universidade de Toronto	Desenvolvimento de Tecnologia Tulsa-Pro	2015
Princess Margaret Cancer Center	Pesquisa de tratamento de câncer de próstata	2016

Colaboradores de desenvolvimento de tecnologia da saúde

A profunda Medical Corp. mantém parcerias estratégicas com empresas especializadas de tecnologia médica:

• Medtronic PLC - Suporte de integração de tecnologia
• Philips Healthcare - Colaboração de Tecnologia de Imagem
• GE Healthcare - Interface avançada de equipamentos de diagnóstico

Urologia e clínicas de radiologia intervencionista

Clínica/Hospital	Localização	Status da parceria
Clínica Mayo	Rochester, Minnesota	Implementação clínica ativa
Clínica de Cleveland	Cleveland, Ohio	Parceria do ensaio clínico

Parceiros de conformidade e certificação regulatórios

Parcerias de certificação regulatória:

• FDA - Processos de aprovação regulatória
• Autoridade de certificação de marca CE - Conformidade do mercado europeu
• Health Canada - Licenciamento de dispositivos médicos

Acordos totais de parceria em 2023: 12 colaborações ativas

Investimento anual de parceria: US $ 2,3 milhões

Profunda Medical Corp. (Prof) - Modelo de Negócios: Atividades -chave

Pesquisa e desenvolvimento de dispositivos médicos

Despesas de P&D para o ano fiscal de 2022: US $ 14,3 milhões

Área de foco em P&D	Investimento
Tecnologia Tulsa-Pro	US $ 8,2 milhões
Inovações de tratamento urológico	US $ 4,1 milhões
Imagem médica avançada	US $ 2 milhões

Inovação em tecnologia terapêutica avançada

Portfólio de patentes a partir de 2023: 37 patentes emitidas

• Tecnologia de ultrassom focada guiada por ressonância magnética
• Sistemas de tratamento de próstata minimamente invasivos
• Plataformas de monitoramento térmico em tempo real

Gerenciamento e execução de ensaios clínicos

Fase de ensaios clínicos	Número de ensaios ativos	Total de participantes
Fase II	3	245 participantes
Fase III	2	387 participantes

Processos de aprovação regulatória

Aparelhas da FDA obtidas: 2 aprovações de dispositivos em 2022

• Dispositivo de tratamento da próstata Tulsa-Pro
• Sistema de monitoramento térmico aprimorado

Estratégias de comercialização de produtos

Total de parcerias comerciais: 7 redes de saúde

Segmento de mercado	Taxa de penetração
Centros de urologia	42%
Centros Médicos Acadêmicos	28%
Hospitais particulares	30%

Profound Medical Corp. (Prof) - Modelo de Negócios: Recursos -Principais

Plataformas proprietárias de tecnologia médica

A profunda Medical Corp. possui a plataforma Tulsa-Pro® (ablação transuretral de ultrassom), um recurso tecnológico essencial para terapia focal no tratamento do câncer de próstata.

Plataforma de tecnologia	Recursos exclusivos	Status de patente
TULSA-PRO®	Ablação do tecido da próstata guiada por ressonância magnética	Múltiplas patentes ativas

Talento especializado em engenharia médica

A partir de 2023, a profunda medicina emprega aproximadamente 55 funcionários em período integral com formação especializada em engenharia e tecnologia médica.

• Experiência avançada de engenharia de dispositivos médicos
• Recursos especializados de desenvolvimento de software
• Especialistas em pesquisa clínica e conformidade regulatória

Patentes avançadas de tecnologia de diagnóstico

Profundo Medical Corp. mantém 17 patentes emitidas Relacionados às tecnologias de imagem médica e tratamento a partir de 2023.

Categoria de patentes	Número de patentes	Cobertura geográfica
Tecnologia central	17	Estados Unidos, Canadá, Europa

Dados de pesquisa clínica e experiência

A empresa acumulou extensos dados de pesquisa clínica de vários ensaios e estudos clínicos envolvendo a plataforma Tulsa-Pro®.

• Mais de 500 tratamentos de pacientes documentados
• Experiência de pesquisa clínica multicêntrica
• Coleta e análise de dados contínuos

Portfólio de propriedade intelectual

Os ativos totais de propriedade intelectual avaliados em aproximadamente US $ 35,2 milhões no período de relatório financeiro de 2022.

Tipo de ativo IP	Avaliação	Importância estratégica
Portfólio de patentes	US $ 35,2 milhões	Alta diferenciação tecnológica

Profound Medical Corp. (Prof) - Modelo de Negócios: Proposições de Valor

Soluções de tratamento médico não invasivas

A profunda Medical Corp. oferece o sistema Tulsa-Pro® com as seguintes especificações:

Parâmetro de tecnologia	Valor específico
Precisão do tratamento	Tecnologia de ultrassom focada guiada por ressonância magnética
Área de tratamento	Ablação do tecido da próstata
Apuração da FDA	Obtido em 2019

Tecnologia terapêutica de precisão

Os principais recursos tecnológicos incluem:

• Monitoramento de temperatura de ressonância magnética em tempo real
• Mecanismo de resfriamento adaptativo
• Entrega precisa de energia térmica

Procedimentos de diagnóstico minimamente invasivos

TULSA-PRO® Características do procedimento:

Procedimento Métrica	Valor
Duração do procedimento	Aproximadamente 2-3 horas
Anestesia necessária	Anestesia geral
Tempo de recuperação do paciente	Normalmente 1-2 dias

Atendimento aprimorado do paciente através de dispositivos médicos avançados

Vantagens de atendimento ao paciente:

• Complicações cirúrgicas reduzidas
• Dano mínimo do tecido
• Recuperação mais rápida em comparação aos métodos cirúrgicos tradicionais

Melhores resultados de tratamento para condições urológicas

Métricas de desempenho do tratamento:

Medida de resultado	Porcentagem/valor
Precisão da ablação do tecido do câncer de próstata	95.6%
Taxa de satisfação do paciente	87.3%
Redução de complicação	62% menor que os métodos tradicionais

Profunda Medical Corp. (Prof) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento profissional médico direto

A partir do quarto trimestre de 2023, a profunda Medical Corp. mantém o envolvimento direto com aproximadamente 87 especialistas urológicos e oncológicos na América do Norte e na Europa.

Métrica de engajamento	Número
Profissionais médicos ativos	87
Regiões geográficas	América do Norte, Europa
Eventos anuais de interação profissional	24

Programas de suporte técnico e treinamento

A infraestrutura de suporte técnico abrange 100% das regiões de implantação de produtos com equipes de suporte dedicadas.

• Tempo médio de resposta: 2,3 horas
• Sessões anuais de treinamento: 18
• Participantes de treinamento: 156 profissionais médicos

Serviços de consulta clínica

Serviços de consulta clínica fornecidos através de 6 consultores especializados em tecnologia médica com experiência combinada de 72 anos.

Métrica de consulta	Valor
Consultores especializados	6
Experiência total de consulta	72 anos
Horário anual de consulta	512

Monitoramento de desempenho do produto em andamento

Monitoramento contínuo do desempenho do sistema Tulsa-Pro em 37 locais clínicos com coleta de dados em tempo real.

• Sites de monitoramento: 37
• Métricas de desempenho rastreadas: 14
• Frequência de coleta de dados: contínuo

Melhoria de tecnologia médica contínua

Investimento de P&D de US $ 4,2 milhões em 2023 dedicado ao aprimoramento da tecnologia e otimização de resultados clínicos.

Métrica de melhoria de tecnologia	Valor
Investimento anual de P&D	US $ 4,2 milhões
Aplicações de patentes	3
Iterações de tecnologia	2

Profunda Medical Corp. (Prof) - Modelo de Negócios: Canais

Equipe direta de vendas de dispositivos médicos

No quarto trimestre 2023, a profunda Medical Corp. manteve uma força de vendas especializada de 18 representantes de vendas diretas direcionadas aos mercados de urologia e radiologia intervencionista.

Métrica da equipe de vendas	2023 dados
Total de representantes de vendas diretas	18
Cobertura geográfica	Estados Unidos, Canadá
Ciclo médio de vendas	6-9 meses

Apresentações da Conferência de Saúde

Em 2023, a profunda médica participou de 7 principais conferências de tecnologia médica.

• Reunião Anual da Associação Americana de Urologia
• Conferência Radiológica da Sociedade da América do Norte
• Congresso da Associação Europeia

Publicações de revistas médicas

A empresa publicou 4 artigos de pesquisa revisados ​​por pares em 2023.

Métrica de publicação	2023 dados
Total de publicações revisadas por pares	4
Revistas primárias	Jornal de Urologia, Radiologia

Plataformas de tecnologia médica online

Plataformas digitais profundas utilizadas médicas para informações sobre o produto e a disseminação de evidências clínicas.

• Site corporativo
• Rede Profissional do LinkedIn
• Webinars de tecnologia médica especializados

Distribuidores de equipamentos médicos especializados

Em 2023, a empresa se envolveu com 12 parceiros especializados de distribuição de equipamentos médicos.

Métrica do Parceiro de Distribuição	2023 dados
Total Distribution Partners	12
Regiões de distribuição primária	América do Norte, mercados europeus selecionados

Profunda Medical Corp. (Prof) - Modelo de Negócios: Segmentos de Clientes

Provedores de saúde urológica

A partir do quarto trimestre 2023, a profunda Medical Corp. tem como alvo os prestadores de serviços de saúde urológicos com sua tecnologia Tulsa-Pro para tratamento de próstata.

Segmento de clientes	Penetração de mercado	Volume anual estimado
Práticas privadas urológicas	37 Práticas na América do Norte	Aproximadamente 1.200 procedimentos por ano

Clínicas de Radiologia Intervencionista

Concentra -se profundos clínicas de radiologia intervencionista especializadas, utilizando tecnologias de tratamento minimamente invasivas.

• Total de clínicas direcionadas: 52 nos Estados Unidos
• Taxa estimada de adoção de mercado: 24%
• Custo médio do procedimento: US $ 6.500 por tratamento

Departamentos Cirúrgicos do Hospital

A empresa tem como alvo departamentos cirúrgicos hospitalares com soluções avançadas de tratamento de próstata.

Tipo de hospital	Número de instalações direcionadas	Procedimentos anuais potenciais
Centros Médicos Acadêmicos	28 instalações	Estimado 750-900 procedimentos anualmente
Hospitais comunitários	45 instalações	Estimado 500-650 procedimentos anualmente

Centros de tratamento médico especializados

O profundo Medical Corp. tem como alvo os centros especializados de tratamento médico, com foco em intervenções urológicas e oncológicas.

• Total de centros especializados identificados: 67
• Concentração geográfica: 82% na América do Norte
• Receita anual potencial por centro: US $ 350.000 a US $ 475.000

Instituições de pesquisa de urologia

As instituições de pesquisa representam um segmento crítico de clientes para validação de tecnologia e estudos clínicos.

Tipo de instituição de pesquisa	Número de instituições	Status de colaboração de pesquisa
Centros de pesquisa acadêmica	19 instituições	Parcerias de pesquisa ativa
Redes de pesquisa clínica	8 redes	Avaliação de tecnologia em andamento

Profunda Medical Corp. (Prof) - Modelo de Negócios: Estrutura de Custo

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a profunda Medical Corp. relatou despesas de pesquisa e desenvolvimento de US $ 14,1 milhões.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2023	US $ 14,1 milhões	76.3%
2022	US $ 12,3 milhões	68.5%

Investimentos de ensaios clínicos

Os investimentos em ensaios clínicos para a profunda Medical Corp. em 2023 totalizaram aproximadamente US $ 8,5 milhões.

• Ensaios clínicos de tecnologia Tulsa-Pro: US $ 5,2 milhões
• Pesquisa de tratamento de câncer de próstata: US $ 3,3 milhões

Custos de fabricação e produção

As despesas de fabricação e produção de 2023 foram de US $ 6,2 milhões.

Categoria de custo	Quantia
Fabricação de equipamentos	US $ 3,7 milhões
Fornecimento de componentes	US $ 1,8 milhão
Trabalho de produção	US $ 0,7 milhão

Despesas de conformidade regulatória

Os custos de conformidade regulatória em 2023 totalizaram US $ 2,3 milhões.

• Custos de envio da FDA: US $ 1,1 milhão
• Processos de certificação: US $ 0,7 milhão
• Monitoramento de conformidade em andamento: US $ 0,5 milhão

Infraestrutura de marketing e vendas

As despesas de marketing e vendas de 2023 foram de US $ 4,6 milhões.

Canal de marketing	Despesa
Marketing digital	US $ 1,9 milhão
Compensação da equipe de vendas	US $ 1,7 milhão
Marketing de conferência e evento	US $ 1,0 milhão

Profunda Medical Corp. (Prof) - Modelo de Negócios: Fluxos de Receita

Vendas de dispositivos médicos

A profunda Medical Corp. gerou US $ 13,8 milhões em receita total para o ano fiscal de 2023, com foco primário nas vendas de dispositivos Tulsa-Pro ™.

Produto	Receita (2023)	Volume de vendas
Sistema Tulsa-Pro ™	US $ 11,2 milhões	23 sistemas vendidos
Componentes descartáveis	US $ 2,6 milhões	Vendas recorrentes

Acordos de licenciamento de tecnologia

A receita de licenciamento de 2023 totalizou US $ 750.000 da Medical Technology Partnerships.

Financiamento da pesquisa clínica

Subsídios de pesquisa e fontes de financiamento contribuíram com aproximadamente US $ 1,5 milhão para fluxos de receita em 2023.

Pesquisa Fonte de financiamento	Quantia
Subsídios do governo	$900,000
Fundações de pesquisa privada	$600,000

Reembolsos de procedimento de diagnóstico

• Reembolso médio por Tulsa-Pro ™ Procedimento: $ 3.750
• Procedimentos anuais estimados: 350-400
• Receita de reembolso de procedimento total: US $ 1,4 milhão - US $ 1,5 milhão

Monetização da propriedade intelectual

O portfólio de patentes gera aproximadamente US $ 250.000 em receita anual de licenciamento.

Categoria IP	Número de patentes	Receita de licenciamento
Tecnologia central	12 patentes ativas	$180,000
Tecnologias periféricas	5 patentes de apoio	$70,000

Profound Medical Corp. (PROF) - Canvas Business Model: Value Propositions

You're looking at the core value Profound Medical Corp. (PROF) delivers to its customers-the physicians and, ultimately, the patients. It's all about offering a superior, less invasive alternative to established procedures, backed by compelling financial and clinical metrics as of late 2025.

The primary value proposition centers on Incision-free, MRI-guided prostate tissue ablation (TULSA-PRO). This technology allows for precise targeting of diseased prostate tissue using sound energy, all while the physician monitors the process in real-time via MRI. This is a significant shift from traditional surgery or radiation.

This precision translates directly into a value proposition of Precise, customizable treatment that protects nerves and functional abilities. The clinical data supports this claim strongly. For instance, perioperative data from the CAPTAIN randomized controlled trial showed that patients treated with robotic radical prostatectomy (RP) took almost three weeks to recover to the same state TULSA Procedure patients reached the very next day. Also, the TULSA Procedure has no associated blood loss and requires no overnight hospital stay.

The customization aspect is evident in how the procedures are being performed across the installed base. Looking at the third quarter of 2025 data, the treatment approach varied significantly:

• 79% were treated for prostate cancer only.
• 14% were hybrid patients (prostate cancer and BPH).
• 4.5% were salvage cases.
• 2.5% were men with BPH only.

Furthermore, the extent of the ablation was highly tailored:

Intention-to-Treat Ablation Type	Percentage of Q3 2025 Procedures
Whole Gland	45%
Sub-Total (More than half the gland)	22%
Hemi-ablations	26%
Focal Therapy	7%

From a financial perspective for Profound Medical Corp., the technology demonstrates a High gross margin of 74.3% on procedures, showing cost-effectiveness for the company. This figure was achieved in the third quarter of 2025, a notable improvement from the 71% gross margin seen in the first quarter of 2025. This high margin is driven by the recurring revenue from consumables used during each TULSA-PRO procedure.

The value proposition extends beyond prostate care to other indications via the Sonalleve platform, offering a Non-invasive treatment for uterine fibroids and palliative pain. Sonalleve is CE marked for treating uterine fibroids and for palliative pain treatment of bone metastases. For specific, localized bone issues, it even holds FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma.

Finally, a key component of the value is the Potential for a single-session, one-and-done procedure. The TULSA Procedure is designed as an incision- and radiation-free treatment performed entirely in a single session that takes just a few hours. This efficiency is also reflected in the reimbursement structure established for 2025. For instance, the Medicare National Average facility payment for CPT 55882 in a Hospital Outpatient setting was set at $12,992, which is 25% higher than the 2025 payment classification for robotic radical proctectomy.

Here's a quick look at the platform's adoption and the resulting revenue quality as of the third quarter of 2025:

• TULSA-PRO Installed Base: 70 systems, with an expectation to reach at least 75 by the end of the year.
• Recurring Revenue (Q3 2025): $4.1 million out of $5.3 million total revenue.
• Procedure Heat Target: Tissue is gently heated to a kill temperature of 55-57°C.

Finance: draft 13-week cash view by Friday.

Profound Medical Corp. (PROF) - Canvas Business Model: Customer Relationships

Direct, high-touch sales and negotiation for capital equipment placement.

The TULSA-PRO installed base reached 70 systems as of September 30, 2025, with an expectation to reach at least 75 installs by the end of the year. Profound Medical Corp. is actively managing a qualified sales pipeline that stood at 93 new systems in the "Verify, Negotiate and Contracting" stages as of Q3 2025. This follows a pipeline of 80 new systems in similar stages in Q2 2025, built upon nearly 500 prospects and over 100 engaged leads reported in that quarter. Capital equipment sales contributed $820,000 in Q1 2025, which dipped to $650,000 in Q2 2025, before increasing to $1.2 million in Q3 2025.

Dedicated clinical support and training for hospital staff.

Support infrastructure is reflected in operating expenses, which were $13.0 million in Q1 2025, rising to $15.4 million in Q2 2025, and settling at approximately $12.8 million in Q3 2025. These expenses cover an enlarged sales force and increased headcount necessary to support commercial expansion. Educational efforts included hosting the Pro-Talk Live! event in February 2025.

Long-term service contracts and consumable supply for recurring revenue.

Recurring revenue streams, which consist of TULSA-PRO® consumables, lease of capital equipment, and extended warranty services, are a key component of customer retention.

Metric	Q1 2025 Amount (USD)	Q2 2025 Amount (USD)	Q3 2025 Amount (USD)
Recurring - non-capital revenue	$1,801,000	$1,600,000	$4,100,000
Percentage of Total Revenue	Approximately 68.7%	Approximately 72.7%	Approximately 77.4%

The gross margin for Profound Medical Corp. improved to 74.3% in Q3 2025, up from 71% in Q1 2025.

Collaborative programs with medical centers to accelerate adoption.

Profound Medical Corp. launched a first-of-its-kind TULSA-PROgram in September 2025 in partnership with Texas Prostate and Dallas Medical Center. This model is designed to bridge private-pay practices and Medicare-participating hospitals. The company is also expanding its market presence through strategic distribution agreements in Canada, Saudi Arabia, Australia, and New Zealand.

Investor relations and public communication on clinical progress.

Public communication highlights clinical milestones and financial health to stakeholders. The company reported its cash position as of March 31, 2025, was $46.4 million, which decreased to $35.2 million by June 30, 2025, and further to approximately $24.8 million as of September 30, 2025. The net loss for Q3 2025 was approximately $8.0 million, or $0.26 per common share, an improvement from the Q3 2024 net loss of approximately $9.4 million. The company is anticipating published data from the CAPTAIN trial in December 2025, which management expects will lead to new guidelines. CEO Arun Menawat presented at the Stifel Healthcare Conference in early November 2025.

• TULSA-PRO treatment applications in Q3 2025:
• 79% for prostate cancer only.
• 14% were hybrid patients (cancer and BPH).
• 4.5% were salvage procedures.
• 2.5% were for BPH only.

Profound Medical Corp. (PROF) - Canvas Business Model: Channels

You're looking at how Profound Medical Corp. gets its TULSA-PRO and Sonalleve systems and services in front of the right clinicians and stakeholders as of late 2025. The strategy clearly splits between direct control in North America and leveraging established partners elsewhere.

Direct sales force focused on North American hospitals and medical centers.

Profound Medical Corp. is deploying its own direct sales team across North America, which they streamlined in the second quarter of 2025 to refine sales processes as they pivot to prioritize capital equipment sales. The company confirmed its sales team was stabilized as of the second quarter of 2025 earnings call. This direct approach is key for managing the TULSA-PRO system adoption in the U.S., where the system has 510(k) clearance from the U.S. Food and Drug Administration (FDA). The company noted a robust TULSA-PRO qualified sales pipeline, which stood at 80 new systems in the Verify, Negotiate, and Contracting stages as of June 30, 2025. This pipeline execution is central to their guidance of achieving 70% to 75% total year-over-year revenue growth for 2025 over 2024 figures.

Exclusive distribution agreements for international markets.

For markets outside North America, Profound Medical Corp. relies on select strategic distribution partners to support the business potential and customer base. This approach was recently reinforced with several key agreements:

• Secured an exclusive distribution and supply agreement with Getz Healthcare for Australia and New Zealand, announced on November 12, 2025.
• Entered into an exclusive distribution agreement with Al Faisaliah Medical Systems in Saudi Arabia, announced on November 11, 2025.
• Regained exclusive distribution rights for Canada from Knight Therapeutics Inc. on November 10, 2025, in exchange for a one-time cash payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian Net Sales for 15 years.

The company is also exploring expanding the partnership with Getz Healthcare to include additional key markets across Asia Pacific. The Sonalleve platform, which is CE marked for uterine fibroids, also has approval from the China National Medical Products Administration for the non-invasive treatment of uterine fibroids.

Clinical presentations at major medical conferences (e.g., RSNA, SUO).

Major medical conferences serve as critical channels for clinical validation and product launches. Profound Medical Corp. actively presented at several key events in late 2025:

• Showcased innovations at the Radiological Society of North America (RSNA) meeting in Chicago (November 30-December 4, 2025) and the Society for Urologic Oncology (SUO) meeting in Phoenix (December 2-5, 2025).
• Launched the TULSA-AI Volume Reduction module for benign prostatic hyperplasia (BPH) at RSNA.
• Presented new clinical data on the TULSA-PRO procedure for prostate cancer at both RSNA and SUO.
• Hosted an investor event during the American Urological Association's (AUA) Annual Meeting in Las Vegas in April 2025.

These presentations feature data, such as the CAPTAIN perioperative trial results, which are intended to drive adoption and potentially influence new clinical guidelines. The company also noted increased travel and conference costs in its operating expenses to support this growth.

Company website and investor relations for defintely reaching stakeholders.

The company utilizes its corporate website, www.profoundmedical.com, for investor relations and to host archived webcasts of calls and events. The website is the source for filings under SEDAR+ and the SEC. The company reported preliminary unaudited total revenues for the third quarter ended September 30, 2025, to be in the range of $5.2 million to $5.3 million USD. This performance reflects the utilization of the installed base, which grew to 67 TULSA-PRO systems as of September 30, 2025, with an expectation to reach at least 75 by the end of the year.

Here's a quick look at the key operational and financial metrics relevant to channel performance as of the third quarter of 2025:

Metric	Value (as of Q3 2025)	Context
TULSA-PRO Installed Base	67 systems (as of Sept 30, 2025)	Up from 60; target of at least 75 by year-end 2025.
Q3 2025 Revenue (Preliminary)	$5.2 million to $5.3 million USD	Represents growth of 84% to 87% over Q3 2024.
Actual Q3 2025 Revenue	$5.29 million USD	Surpassed market expectation of $4.98 million.
Q3 2025 Gross Margin (Expected)	Approximately 72%	Compared to 64% in the prior year period.
Total Revenue (TTM)	$14.30 Million USD	Up 67.94% year-over-year (as of Sept 30, 2025).
Canadian Royalty Rate	5%	On Canadian Net Sales for 15 years, following rights regaining.

The company's cash position as of June 30, 2025, was $35.2 million, which supports the operating expenses associated with expanding the commercial organization and travel for conferences. Finance: draft 13-week cash view by Friday.

Profound Medical Corp. (PROF) - Canvas Business Model: Customer Segments

You're looking at the customer base for Profound Medical Corp. as of late 2025, primarily driven by the TULSA-PRO system utilization following their strong third quarter results.

Hospitals and specialized medical centers acquiring capital equipment.

These institutions are the direct purchasers of the durable TULSA-PRO system, which is used in conjunction with their existing MRI scanner. The installed base, which is key to recurring revenue from consumables, stood at 70 systems as of September 30, 2025. Management reiterated confidence in reaching at least 75 installs by the end of the year. The qualified sales pipeline for new systems was robust, standing at 93 new systems in the Verify, Negotiate, and Contracting stages in Q3 2025. Revenue from the one-time sale of capital equipment in Q3 2025 was $1.2 million out of total revenue of approximately $5.3 million for the quarter.

Urologists and interventional radiologists performing the procedures.

These are the key users who drive the recurring revenue stream, which was $4.1 million in Q3 2025 from consumables, leases, and warranties. The TULSA Procedure is an incision- and radiation-free, one-and-done procedure. The company is focused on U.S. commercialization with a direct sales team. The new TULSA-AI Volume Reduction module, which debuted in late 2025, is specifically designed to streamline workflow and compress procedure times, allowing sites to schedule multiple cases in a single day. This efficiency push targets the same operational arguments used by high-volume BPH alternatives.

Prostate cancer patients (the majority, 79% of Q3 2025 procedures).

This group represents the core utilization base for the TULSA-PRO system. The procedure treats the entire prostate disease spectrum. Here's the quick math on the patient mix from Q3 2025 procedures:

Patient Indication	Percentage of TULSA Procedures (Q3 2025)
Prostate Cancer Only	79%
Hybrid (Cancer and BPH)	14%
Salvage Therapy (Radio-recurrent)	4.5%
BPH Only	2.5%

For the cancer-only segment, the breakdown by Gleason Grade Group (GG) was:

• GG1: 10%
• GG2: 53%
• GG3: 28%
• GG4 & GG5: 9%

Patients with Benign Prostatic Hyperplasia (BPH) and hybrid cases.

The introduction of the TULSA-AI Volume Reduction module in late 2025 is a strategic move to capture this larger market. Profound projects this module could expand its annual addressable patient pool to roughly 600,000 patients. In Q3 2025, patients with BPH only accounted for 2.5% of procedures, while hybrid cases (cancer and BPH) made up 14%.

Patients requiring salvage therapy for radio-recurrent cancer.

This is a specific, high-need niche within the overall patient population. In the third quarter of 2025, patients requiring salvage therapy for radio-recurrent cancer represented 4.5% of the TULSA Procedures performed. The TULSA Procedure offers an incision- and radiation-free option for these patients.

Profound Medical Corp. (PROF) - Canvas Business Model: Cost Structure

You're looking at the expenses Profound Medical Corp. is incurring to drive its commercial growth and clinical milestones as of late 2025. Honestly, the cost structure is heavily weighted toward expansion and development right now, which is typical for a commercial-stage medical device company scaling its footprint.

High Selling, General, and Administrative (SG&A) expenses from sales force expansion

The push to grow the TULSA-PRO installed base is a major cost driver. You see this reflected in the operating expenses rising year-over-year. For the third quarter of 2025, total operating expenses were approximately $12.8 million, up from $10.8 million in the third quarter of 2024. This increase was explicitly tied to several factors supporting the commercial ramp.

The key components driving this higher SG&A include:

• Increased headcount and increased sales force size.
• Higher commission payments tied to sales performance.
• Increased travel and infrastructure costs to support the growing business.

The second quarter of 2025 showed even higher operating expenses at approximately $15.4 million, which also pointed to higher headcount and sales force expansion.

Significant R&D investment, totaling $10.9 million for the nine months of 2025

Profound Medical Corp. continues to fund future innovation and clinical validation. You are required to note the significant R&D spend dedicated to advancing the platform. The investment in Research and Development for the first nine months of 2025 totaled $10.9 million.

This investment supports pipeline development, including the TULSA-AI Volume Reduction software, which soft-launched in Q4 2025, and the integration with Siemens Free.Max.

Costs of goods sold for TULSA-PRO systems and consumables

The Cost of Goods Sold (COGS) is the direct cost associated with generating revenue. Profound Medical Corp. achieved a gross margin of 74.3% in the third quarter of 2025. Given the Q3 2025 revenue was $5.3 million, the implied COGS for that quarter was approximately $1.35 million ($5.3 million (1 - 0.743)).

Revenue generation in Q3 2025 broke down as follows:

Revenue Component	Q3 2025 Amount (USD)
Recurring Revenue (Consumables, Lease, Services)	$4.1 million
One-Time Sale of Capital Equipment (TULSA-PRO systems)	$1.2 million

The recurring revenue stream, which is tied to consumables used in the TULSA Procedure, is key to margin stability, as evidenced by the 1,119 basis point year-over-year improvement in gross margin.

Clinical trial costs, particularly for the CAPTAIN trial enrollment

Clinical validation is a necessary, non-recurring cost that impacts quarterly expenses. The pivotal CAPTAIN trial, which compared TULSA to robotic radical prostatectomy, was a significant cost factor, particularly in the first half of 2025.

The increased operating expenses in the second quarter of 2025, which reached $15.4 million, were directly attributed to:

• Increased enrolment for the CAPTAIN trial.
• Associated treatments and recruitment efforts.

Management announced that the recruitment for the CAPTAIN trial was completed as of August 2025.

General corporate overhead and public company compliance costs

This category covers the fixed and semi-fixed costs of running a publicly traded entity. While not broken out separately, these costs are embedded within the total operating expenses, which totaled $12.8 million in Q3 2025.

These overhead costs cover necessary functions such as:

• General corporate administration.
• Public company compliance, including SEC filings and investor relations.
• Base salaries for non-sales/R&D personnel.

The company's net loss for Q3 2025 was approximately $8.0 million, reflecting these operating costs against the $5.3 million in revenue.

Profound Medical Corp. (PROF) - Canvas Business Model: Revenue Streams

You're looking at the core ways Profound Medical Corp. (PROF) brings in cash as of late 2025, which is heavily weighted toward repeat business, a good sign for a medical device company.

The revenue structure is clearly bifurcated between the initial sale of the high-value TULSA-PRO capital equipment and the ongoing revenue generated from using that equipment. For the third quarter of 2025, the total revenue hit a record $5.3 million. This performance showed an 87% increase year-over-year from $2.8 million in Q3 2024.

The real engine for the business, however, is the recurring side. Recurring revenue, which covers consumables, leases, and service contracts, was $4.1 million in Q3 2025, making it the majority of the sales generated that quarter. This recurring stream is essential because it provides a more predictable financial base than relying solely on large, lumpy capital sales.

Here is the quick math on how the Q3 2025 revenue broke down:

Revenue Component	Q3 2025 Amount (USD)	Source Type
Sale or lease of TULSA-PRO capital equipment	$1.2 million	One-time/Capital
Recurring revenue (Consumables, Leases, Service)	$4.1 million	Recurring
Total Revenue	$5.3 million	Total

The recurring revenue component is explicitly tied to the installed base of the TULSA-PRO system, which stood at 70 systems as of the end of Q3 2025, with management expecting to reach at least 75 installs by the end of the year. This recurring revenue from TULSA-PRO consumables, leases, and service contracts is the foundation of the business model.

Beyond the primary TULSA-PRO revenue, Profound Medical Corp. also generates revenue from its other platform:

• Revenue from Sonalleve system sales and related consumables/services.
• The recurring revenue stream also incorporates service contracts and leases for both TULSA-PRO and Sonalleve platforms.
• The company is actively expanding market access for both TULSA-PRO and Sonalleve through new distribution agreements in regions like Saudi Arabia.

To be fair, the $1.2 million from capital equipment sales represents a significant, though less predictable, portion of the total revenue. The gross margin on this total revenue was strong at 74.3% for the quarter.

Finance: draft 13-week cash view by Friday.